|
1
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I; EUROCARE-4 Working
Group. Recent cancer survival in Europe: A 2000–02 period analysis
of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kong Y, Bai PS, Sun H, Nan KJ, Chen NZ and
Qi XG: The deoxycholic acid targets miRNA-dependent CAC1 gene
expression in multidrug resistance of human colorectal cancer. Int
J Biochem Cell Biol. 44:2321–2332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yasunaga M and Matsumura Y: Role of SLC6A6
in promoting the survival and multidrug resistance of colorectal
cancer. Sci Rep. 4:48522014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nooter K and Sonneveld P: Clinical
relevance of P-glycoprotein expression in haematological
malignancies. Leuk Res. 18:233–243. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leith C: Multidrug resistance in leukemia.
Curr Opin Hematol. 5:287–291. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharma R, Awasthi YC, Yang Y, Sharma A,
Singhal SS and Awasthi S: Energy dependent transport of xenobiotics
and its relevance to multidrug resistance. Curr Cancer Drug
Targets. 3:89–107. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jullien-Flores V, Dorseuil O, Romero F,
Letourneur F, Saragosti S, Berger R, Tavitian A, Gacon G and
Camonis JH: Bridging Ral GTPase to Rho pathways. RLIP76, a Ral
effector with CDC42/Rac GTPase-activating protein activity. J Biol
Chem. 270:22473–22477. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park SH and Weinberg RA: A putative
effector of Ral has homology to Rho/Rac GTPase activating proteins.
Oncogene. 11:2349–2355. 1995.PubMed/NCBI
|
|
11
|
Awasthi S, Cheng J, Singhal SS, Saini MK,
Pandya U, Pikula S, Bandorowicz-Pikula J, Singh SV, Zimniak P and
Awasthi YC: Novel function of human RLIP76: ATP-dependent transport
of glutathione conjugates and doxorubicin. Biochemistry.
39:9327–9334. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singhal SS, Singhal J, Nair MP, Lacko AG,
Awasthi YC and Awasthi S: Doxorubicin transport by RALBP1 and ABCG2
in lung and breast cancer. Int J Oncol. 30:717–725. 2007.PubMed/NCBI
|
|
13
|
Singhal SS, Sehrawat A, Sahu M, Singhal P,
Vatsyayan R, Rao Lelsani PC, Yadav S and Awasthi S: Rlip76
transports sunitinib and sorafenib and mediates drug resistance in
kidney cancer. Int J Cancer. 126:1327–1338. 2010.
|
|
14
|
Singhal SS, Sehrawat A, Mehta A, Sahu M
and Awasthi S: Functional reconstitution of RLIP76 catalyzing
ATP-dependent transport of glutathione-conjugates. Int J Oncol.
34:191–199. 2009.
|
|
15
|
Drake KJ, Singhal J, Yadav S, Nadkar A,
Pungaliya C, Singhal SS and Awasthi S: RALBP1/RLIP76 mediates
multidrug resistance. Int J Oncol. 30:139–144. 2007.
|
|
16
|
Awasthi S, Singhal SS, Srivastava SK,
Zimniak P, Bajpai KK, Saxena M, Sharma R, Ziller SA III, Frenkel EP
and Singh SV: Adenosine triphosphate-dependent transport of
doxorubicin, daunomycin, and vinblastine in human tissues by a
mechanism distinct from the P-glycoprotein. J Clin Invest.
93:958–965. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Awasthi S, Singhal SS, Pandya U, Gopal S,
Zimniak P, Singh SV and Awasthi YC: ATP-Dependent colchicine
transport by human erythrocyte glutathione conjugate transporter.
Toxicol Appl Pharmacol. 155:215–226. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Awasthi S, Singhal SS, Singhal J, Yang Y,
Zimniak P and Awasthi YC: Role of RLIP76 in lung cancer doxorubicin
resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung
cancer cells and synergistically increase doxorubicin cytotoxicity.
Int J Oncol. 22:721–732. 2003.PubMed/NCBI
|
|
19
|
Yadav S, Zajac E, Singhal SS, Singhal J,
Drake K, Awasthi YC and Awasthi S: POB1 over-expression inhibits
RLIP76-mediated transport of glutathione-conjugates, drugs and
promotes apoptosis. Biochem Biophys Res Commun. 328:1003–1009.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singhal SS, Singhal J, Yadav S, Dwivedi S,
Boor PJ, Awasthi YC and Awasthi S: Regression of lung and colon
cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding
protein 1). Cancer Res. 67:4382–4389. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singhal SS, Roth C, Leake K, Singhal J,
Yadav S and Awasthi S: Regression of prostate cancer xenografts by
RLIP76 depletion. Biochem Pharmacol. 77:1074–1083. 2009. View Article : Google Scholar :
|
|
22
|
Singhal SS, Awasthi YC and Awasthi S:
Regression of melanoma in a murine model by RLIP76 depletion.
Cancer Res. 66:2354–2360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leake K, Singhal J, Nagaprashantha LD,
Awasthi S and Singhal SS: RLIP76 regulates PI3K/Akt signaling and
chemo-radiotherapy resistance in pancreatic cancer. PLoS One.
7:e345822012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Q, Qian J, Wang J, Luo C, Chen J, Hu
G and Lu Y: Knockdown of RLIP76 expression by RNA interference
inhibits invasion, induces cell cycle arrest, and increases
chemosensitivity to the anticancer drug temozolomide in glioma
cells. J Neurooncol. 112:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Singhal SS, Yadav S, Vatsyayan R,
Chaudhary P, Borvak J, Singhal J and Awasthi S: Increased
expression of cdc2 inhibits transport function of RLIP76 and
promotes apoptosis. Cancer Lett. 283:152–158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu Y and Mivechi NF: HSF-1 interacts with
Ral-binding protein 1 in a stress-responsive, multiprotein complex
with HSP90 in vivo. J Biol Chem. 278:17299–17306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu
YC, Hu GH, Luo C and Chen JX: RLIP76 is overexpressed in human
glioblastomas and is required for proliferation, tumorigenesis and
suppression of apoptosis. Carcinogenesis. 34:916–926. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jullien-Flores V, Mahé Y, Mirey G,
Leprince C, Meunier-Bisceuil B, Sorkin A and Camonis JH: RLIP76, an
effector of the GTPase Ral, interacts with the AP2 complex:
Involvement of the Ral pathway in receptor endocytosis. J Cell Sci.
113:2837–2844. 2000.PubMed/NCBI
|
|
29
|
Quaroni A and Paul EC: Cytocentrin is a
Ral-binding protein involved in the assembly and function of the
mitotic apparatus. J Cell Sci. 112:707–718. 1999.PubMed/NCBI
|
|
30
|
Awasthi S, Singhal SS, Sharma R, Zimniak P
and Awasthi YC: Transport of glutathione conjugates and
chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between
G-protein and tyrosine kinase signaling and drug resistance. Int J
Cancer. 106:635–646. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Awasthi S, Singhal SS, Awasthi YC, Martin
B, Woo JH, Cunningham CC and Frankel AE: RLIP76 and Cancer. Clin
Cancer Res. 14:4372–4377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Awasthi YC, Singhal SS, Gupta S, Ahmad H,
Zimniak P, Radominska A, Lester R and Sharma R: Purification and
characterization of an ATPase from human liver which catalyzes ATP
hydrolysis in the presence of the conjugates of bilirubin bile
acids and glutathione. Biochem Biophys Res Commun. 175:1090–1096.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Awasthi S, Singhal SS, Singhal J, Cheng J,
Zimniak P and Awasthi YC: Role of RLIP76 in lung cancer doxorubicin
resistance: II. Doxorubicin transport in lung cancer by RLIP76. Int
J Oncol. 22:713–720. 2003.PubMed/NCBI
|
|
34
|
Yadav S, Singhal SS, Singhal J,
Wickramarachchi D, Knutson E, Albrecht TB, Awasthi YC and Awasthi
S: Identification of membrane-anchoring domains of RLIP76 using
deletion mutant analyses. Biochemistry. 43:16243–16253. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stuckler D, Singhal J, Singhal SS, Yadav
S, Awasthi YC and Awasthi S: RLIP76 transports vinorelbine and
mediates drug resistance in non-small cell lung cancer. Cancer Res.
65:991–998. 2005.PubMed/NCBI
|
|
36
|
Singhal SS, Yadav S, Singhal J, Zajac E,
Awasthi YC and Awasthi S: Depletion of RLIP76 sensitizes lung
cancer cells to doxorubicin. Biochem Pharmacol. 70:481–488. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Awasthi S, Cheng JZ, Singhal SS, Pandya U,
Sharma R, Singh SV, Zimniak P and Awasthi YC: Functional reassembly
of ATP-dependent xenobiotic transport by the N- and C-terminal
domains of RLIP76 and identification of ATP binding sequences.
Biochemistry. 40:4159–4168. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Su JL, Lin MT, Hong CC, Chang CC, Shiah
SG, Wu CW, Chen ST, Chau YP and Kuo ML: Resveratrol induces
FasL-related apoptosis through Cdc42 activation of
ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells.
Carcinogenesis. 26:1–10. 2005. View Article : Google Scholar
|
|
39
|
Rohwer N and Cramer T: Hypoxia-mediated
drug resistance: Novel insights on the functional interaction of
HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang H, Zhao L, Zhu LT, Wang Y, Pan D, Yao
J, You QD and Guo QL: Wogonin reverses hypoxia resistance of human
colon cancer HCT116 cells via downregulation of HIF-1α and
glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinog.
53(Suppl 1): E107–E118. 2014. View
Article : Google Scholar
|
|
41
|
Cho K, Shin HW, Kim YI, Cho CH, Chun YS,
Kim TY and Park JW: Mad1 mediates hypoxia-induced doxorubicin
resistance in colon cancer cells by inhibiting mitochondrial
function. Free Radic Biol Med. 60:201–210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Murono K, Tsuno NH, Kawai K, Sasaki K,
Hongo K, Kaneko M, Hiyoshi M, Tada N, Nirei T, Sunami E, et al:
SN-38 overcomes chemoresistance of colorectal cancer cells induced
by hypoxia, through HIF1alpha. Anticancer Res. 32:865–872.
2012.PubMed/NCBI
|
|
43
|
Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin
P, Fan Z and Li Q: COX-2 contributes to P-glycoprotein-mediated
multidrug resistance via phosphorylation of c-Jun at Ser63/73 in
colorectal cancer. Carcinogenesis. 32:667–675. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Choudhuri S and Klaassen CD: Structure,
function, expression, genomic organization, and single nucleotide
polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP)
efflux transporters. Int J Toxicol. 25:231–259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Higgins CF: Multiple molecular mechanisms
for multidrug resistance transporters. Nature. 446:749–757. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sharom FJ: ABC multidrug transporters:
Structure, function and role in chemoresistance. Pharmacogenomics.
9:105–127. 2008. View Article : Google Scholar
|
|
47
|
Poon RT, Fan ST, Ng IO, Lo CM, Liu CL and
Wong J: Different risk factors and prognosis for early and late
intrahepatic recurrence after resection of hepatocellular
carcinoma. Cancer. 89:500–507. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Singhal SS, Singhal J, Figarola J, Horne D
and Awasthi S: RLIP76 targeted therapy for kidney cancer. Pharm
Res. 32:3123–3136. 2015. View Article : Google Scholar : PubMed/NCBI
|
